BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide composed of 15 amino acids, originally derived from a protein found in human gastric juice. It is one of the most widely studied peptides in preclinical research, with over 100 peer-reviewed publications investigating its effects on soft tissue healing, gastrointestinal mucosal protection, angiogenesis, and tendon-to-bone healing in animal models. Research applications explore BPC-157's role in fibroblast proliferation, collagen synthesis, and growth hormone receptor modulation. The peptide is commonly supplied as a lyophilized powder requiring reconstitution with bacteriostatic water before use. The FDA removed BPC-157 from Category 2 restriction in April 2026, with Pharmacy Compounding Advisory Committee (PCAC) review scheduled for July 2026 to determine its eligibility for the official 503A Bulks List.
Directory listing last reviewed July 2026.